Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$27,000.00
A randomized double blinded controlled trial for the treatment of persistent post-concussion symptoms with psilocybin assisted therapy: A safety and feasibility trial
FY 2024-25
Summary
Persistent post-concussion symptoms (PPCS) are experienced by up to a third of those who suffer a concussion. Symptoms can include headaches, dizziness, fatigue, irritability, sleep difficulties, anxiety, cognitive difficulties, memory problems, and sensitivity to noise and light. These symptoms can vary in severity and significantly impact daily function. Unfortunately, there is no cure or evidence-based standard treatment these patients can turn to, as PPCS can vary for each patient. While treatments such as psychotherapy, pharmacotherapy, exercise therapy, and physiotherapy are available, they may not be sufficient for all patients. Many patients struggle to navigate these treatments without adequate guidance, limiting their effectiveness.Psychedelic-assisted psychotherapy is a novel treatment approach that has shown promise in treating similar symptoms as PPCS, such as headaches, sleep difficulties, cognitive difficulties, anxiety, and depression .This approach involves the therapeutic administration of a psychedelic substance, which is paired with psychotherapy before, during, and after medication administration.Our clinical trial aims to determine if psilocybin-assisted therapy is a safe, feasible, and effective intervention for adults with PPCS. Participants will be randomized to either a small control dose or a larger treatment dose of psilocybin, followed by 5 sessions of manualized therapy adapted for patients with brain injury.By measuring outcomes such as recruitment, adherence, safety, and preliminary efficacy, this novel trial aims to evaluate the potential for psilocybin-assisted therapy to aid in recovery for those suffering from PPCS.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
529775
Name
Hancock Mackenzie
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A randomized double blinded controlled trial for the treatment of persistent post-concussion symptoms with psilocybin assisted therapy: A safety and feasibility trial
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acceptance And Commitment Therapy; Concussion; Persistent Post-Concussion Symptoms; Psilocybin; Psychedelic; Psychotherapy; Traumatic Brain Injury
Abstract
Persistent post-concussion symptoms (PPCS) are experienced by up to a third of those who suffer a concussion. Symptoms can include headaches, dizziness, fatigue, irritability, sleep difficulties, anxiety, cognitive difficulties, memory problems, and sensitivity to noise and light. These symptoms can vary in severity and significantly impact daily function. Unfortunately, there is no cure or evidence-based standard treatment these patients can turn to, as PPCS can vary for each patient. While treatments such as psychotherapy, pharmacotherapy, exercise therapy, and physiotherapy are available, they may not be sufficient for all patients. Many patients struggle to navigate these treatments without adequate guidance, limiting their effectiveness.Psychedelic-assisted psychotherapy is a novel treatment approach that has shown promise in treating similar symptoms as PPCS, such as headaches, sleep difficulties, cognitive difficulties, anxiety, and depression .This approach involves the therapeutic administration of a psychedelic substance, which is paired with psychotherapy before, during, and after medication administration.Our clinical trial aims to determine if psilocybin-assisted therapy is a safe, feasible, and effective intervention for adults with PPCS. Participants will be randomized to either a small control dose or a larger treatment dose of psilocybin, followed by 5 sessions of manualized therapy adapted for patients with brain injury.By measuring outcomes such as recruitment, adherence, safety, and preliminary efficacy, this novel trial aims to evaluate the potential for psilocybin-assisted therapy to aid in recovery for those suffering from PPCS.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hancock, Mackenzie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~